Nanodelivery of STING agonists against cancer and infectious diseases.
Sign Up to like & getrecommendations! Published in 2021 at "Molecular aspects of medicine"
DOI: 10.1016/j.mam.2021.101007
Abstract: Vaccination is a modality that has been widely explored for the treatment of various diseases. To increase the potency of vaccine formulations, immunostimulatory adjuvants have been regularly exploited, and the stimulator of interferon genes (STING)… read more here.
Keywords: infectious diseases; nanodelivery sting; sting agonists; cancer infectious ... See more keywords
Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00634
Abstract: Activation of the stimulator of interferon genes (STING) pathway to achieve antitumor response is an attractive approach for cancer immunotherapy. In this study, we report the identification of BSP16 (LF250) as a potent, orally available… read more here.
Keywords: selenium containing; antitumor; sting agonists; orally available ... See more keywords
Sensitizing Tumors to Immune Checkpoint Blockage via STING Agonists Delivered by Tumor-Penetrating Neutrophil Cytopharmaceuticals.
Sign Up to like & getrecommendations! Published in 2023 at "ACS nano"
DOI: 10.1021/acsnano.2c11764
Abstract: Immune checkpoint inhibitors (ICIs) have displayed potential efficacy in triple-negative breast cancer (TNBC) treatment, while only a minority of patients benefit from ICI therapy currently. Although activation of the innate immune stimulator of interferon genes… read more here.
Keywords: immune checkpoint; neutrophil cytopharmaceuticals; sting agonists; tumor ... See more keywords
Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation.
Sign Up to like & getrecommendations! Published in 2022 at "International immunology"
DOI: 10.1093/intimm/dxac012
Abstract: Agonists for TLR9 and STING offer therapeutic applications both as anti-tumor agents and vaccine adjuvants, though their clinical applications are limited; the clinically available TLR9 agonist is a weak IFN inducer and STING agonists induce… read more here.
Keywords: immunity; tlr9 sting; anti tumor; sting agonists ... See more keywords
Abstract B068: An in vitro cellular functional STING pathway assay to measure the potency of STING agonists, using interferon-β response
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-b068
Abstract: Introduction and Relevance: We have developed an in vitro cellular functional STING pathway assay that can be used to screen for potential therapeutic agents in drug discovery. Stimulator of interferon genes (STING, or TMEM173) is… read more here.
Keywords: cellular functional; interferon; sting agonists; vitro cellular ... See more keywords
Abstract 3317: Discovery of novel STING agonists with robust anti-tumor activity
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-3317
Abstract: Introduction: Stimulator of interferon genes (STING) is an endoplasmic reticulum (ER) membrane signaling protein, which plays a key role in the sensing of cytoplasmic DNA arising from bacterial and viral infection, as well as self-DNA.… read more here.
Keywords: novel sting; sting agonists; cancer; activity ... See more keywords
Abstract 6397: Eribulin acts as an immune adjuvant to enhance the antitumor efficacy of STING agonists in triple-negative breast cancer models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6397
Abstract: Triple-negative breast cancer (TNBC) is a heterogenous subtype of breast cancer lacking effective targeted treatment options. However, TNBC typically has a higher mutational burden and greater degree of immunogenicity than other breast tumors, making immunotherapy… read more here.
Keywords: sting agonists; breast; breast cancer; eribulin ... See more keywords
Abstract B43: Novel small-molecule human STING agonists generate robust Type I interferon responses in tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer immunology research"
DOI: 10.1158/2326-6074.tumimm17-b43
Abstract: Background: A significant proportion of human cancers grow unchecked by the immune system. These cold or non-inflamed tumors do not have a T cell infiltrate and it has been shown that activation of innate immune… read more here.
Keywords: crd 100; human sting; small molecule; sting agonists ... See more keywords
Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1093240
Abstract: Immunotherapy has greatly enhanced the effectiveness of cancer treatments, but the efficacy of many current immunotherapies is still limited by the tumor-suppressive immune microenvironment. Multiple studies have shown that activating the stimulation of IFN genes… read more here.
Keywords: immune microenvironment; tumor immune; nanomedicines targeting; sting agonists ... See more keywords
STING Agonists as Cancer Therapeutics
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13112695
Abstract: Simple Summary Immunotherapies have revolutionized the field of cancer therapeutics, yet a substantial subset of patients fail to respond. Recent efforts have focused on identifying targets that could elicit or augment anti-tumor immune responses. One… read more here.
Keywords: sting agonists; sting pathway; cancer; cancer therapeutics ... See more keywords
The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14235962
Abstract: Simple Summary Microtubule-targeting agents are a class of chemotherapeutics used to treat triple-negative breast cancer (TNBC). These include drugs such as eribulin that depolymerize microtubules, as well as microtubule stabilizing taxanes such as paclitaxel. TNBC… read more here.
Keywords: breast cancer; eribulin; microtubule; sting agonists ... See more keywords